Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses

Abstract

Current vaccines against influenza virus infection rely on the induction of neutralizing antibodies targeting the globular head of the viral hemagglutinin (HA). Protection against seasonal antigenic drift or sporadic pandemic outbreaks requires further vaccine development to induce cross-protective humoral responses, potentially to the more conserved HA stalk region. Here, we present a novel viral vaccine adjuvant comprised of two synthetic ligands for Toll-like receptor 4 (TLR4) and TLR7. 1Z105 is a substituted pyrimido[5,4-b]indole specific for the TLR4-MD2 complex, and 1V270 is a phospholipid-conjugated TLR7 agonist. Separately, 1Z105 induces rapid Th2-associated IgG1 responses, and 1V270 potently generates Th1 cellular immunity. 1Z105 and 1V270 in combination with recombinant HA from the A/Puerto Rico/8/1934 strain (rPR/8 HA) effectively induces rapid and sustained humoral immunity that is protective against lethal challenge with a homologous virus. More importantly, immunization with the combined adjuvant and rPR/8 HA, a commercially available split vaccine, or chimeric rHA antigens significantly improves protection against both heterologous and heterosubtypic challenge viruses. Heterosubtypic protection is associated with broadly reactive antibodies to HA stalk epitopes. Histological examination and cytokine profiling reveal that intramuscular (i.m.) administration of 1Z105 and 1V270 is less reactogenic than a squalene-based adjuvant, AddaVax. In summary, the combination of 1Z105 and 1V270 with a recombinant HA induces rapid, long-lasting, and balanced Th1-and Th2-type immunity; demonstrates efficacy in a variety of murine influenza virus vaccine models assaying homologous, heterologous, and heterosubtypic challenge viruses; and has an excellent safety profile. IMPORTANCENovel adjuvants are needed to enhance immunogenicity and increase the protective breadth of influenza virus vaccines to reduce the seasonal disease burden and ensure pandemic preparedness. We show here that the combination of synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands is a potent adjuvant for recombinant influenza virus hemagglutinin, inducing rapid and sustained immunity that is protective against influenza viruses in homologous, heterologous, and heterosubtypic challenge models. Combining TLR4 and TLR7 ligands balances Th1-and Th2-type immune responses for long-lived cellular and neutralizing humoral immunity against the viral hemagglutinin. The combined adjuvant has an attractive safety profile and the potential to augment seasonal-vaccine breadth, contribute to a broadly neutralizing universal vaccine formulation, and improve response time in an emerging pandemic. Influenza A and B viruses remain a substantial public health burden, with seasonal epidemics resulting in significant morbidity, mortality, and economic loss (1-3). Pandemic outbreaks occur when antigenically novel influenza A viruses emerge in a population with little preexisting immunity (4). Pandemic viruses spread more rapidly and cause more severe di...

Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model

“…The enhanced clearance of bacteria following B. pertussis challenge of mice immunized with aP+alum-TLR7a is likely to be mediated by a combination of different immune responses, including cytokine secretion by Th1 and Th17 cells, leading to enhanced recruitment and activation of phagocytic cells, and higher titres of IgG2a/b antibodies titres, that are known to promote opsonization and complement-mediated killing of bacterial cells. Similar to our findings, addition of a TLR7 agonist to an influenza vaccine formulation promoted protective IFN-c and IgG2a responses in mice [20]. Importantly, TLR7-adjuvanted influenza vaccine produced potent immune responses with low reactogenicity.…”

Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques

“…A striking result to emerge from this study was that specific combinations of TLR ligands induced a greatly enhanced antibody response and long-lived germinal center (GC) responses similar to those observed in live viral infections (14). The observation that specific combinations of TLR ligands enhance antibody responses has been confirmed by recent studies (15)(16)(17).…”

“…Animals were bled ϳ4 weeks before primary immunization for baseline analysis of serological and cellular immune responses. Animals were immunized 4 times at weeks 0, 8,16, and 25. Animals were rested for 4 months and subjected to a series of challenges with 20,000 TCID 50 (0.5 to 1.0 AID 50 ) every week for 12 weeks.…”

Translating nucleic acid-sensing pathways into therapies

“…Agonists of nucleic acid recognition pathways are promising novel candidates that license DCs for the induction of protective immune responses mediated by both T H 1 cells and cytotoxic CD8 + T cells 59 . The combined use of different agonists may prove even more powerful, as recent data have indicated that co-engagement of multiple nucleic acid receptors elicited the most potent immune responses in preclinical trials of vaccine adjuvants 60,61 .…”